Johnson & Johnson said it will move forward with the $2.1 billion sale of its diabetes monitoring unit LifeScan Inc. to Platinum Equity, a private investment firm.
J&J said in March that it had received a $2.1 billion binding offer from Platinum Equity. On Tuesday, it said it had formally accepted that offer. The health-care company said it expects the deal to close by the end of the year.
New Brunswick, New Jersey-based J&J has been selling off smaller units as the health-care conglomerate gets out of businesses where it’s not a leader. Last week, it announced the sale of ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.